Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Alabama Research

Neither a doctor nor a teaching hospital

Research payments

$3,302,667

361 payments

Through program year 2025, Central Alabama Research is reported as receiving $3,302,667 in research payments, across 361 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $626,781 98
2024 Research $954,586 32
2023 Research $732,851 101
2022 Research $142,443 62
2021 Research $253,001 17
2020 Research $223,873 15
2019 Research $369,134 36

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca UK Limited $1,435,364 3 payments
  2. Genentech, Inc. $506,377 8 payments
  3. Novartis Pharmaceuticals Corporation $445,879 14 payments
  4. Seattle Genetics, Inc. $325,632 12 payments
  5. Pfizer Inc. $275,181 14 payments
  6. Novo Nordisk AS $152,125 30 payments
  7. Ipsen Innovation $49,012 88 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $27,397 2 payments
  9. AstraZeneca Pharmaceuticals LP $20,776 2 payments
  10. Celgene Corporation $16,200 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $1,435,364 3 payments
  2. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $397,855 8 payments
  3. A phase IIIB surveillance study of susceptibility to baloxavir marboxil $333,577 6 payments
  4. A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) $325,632 12 payments
  5. A Randomized Doubleblind Placebocontrolled Activecomparator Multicenter Phase 3 Study of Brentuximab Vedotin Or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed Or Refractory Diffuse Large Bcell Lymphoma Dlbcl $184,143 3 payments
  6. PH III Study of Safety Efficacy of Cap Endonuclease in Pediatric Patients 1 12 Years $172,800 2 payments
  7. Ex9536-4388 $132,741 29 payments
  8. A Phase 3 Randomized Doubleblind Placebocontrolled 26Week Multicenter Study With A 78Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo $90,846 7 payments
  9. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $40,751 4 payments
  10. Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $30,236 41 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record